4 years ago
Ochre Bio Secures $9.6M in Seed Financing for RNA Medicines
Ochre Bio, a UK-based biotech company, has raised $9.6 million in seed financing led by Khosla Ventures
The company will use the funds to advance the development of its RNA therapies and expand its deep phenotyping platform.
ProblemHealthcare
"Chronic liver diseases are a major health challenge, with limited treatment options and a significant unmet need for effective therapies."
Solution
"Ochre Bio develops RNA medicines for chronic liver diseases by leveraging a deep phenotyping platform to identify and validate new liver targets, and by testing therapeutics in explanted human livers maintained extracorporeally. This approach allows them to digitize liver biology at scale and uncover novel targets for therapeutic intervention."
